The Lancet Oncology
Fecha de publicación: 10 august 2018
Autores: Vera Lidwina Negenborn, MD. Danny Aschwin Young-Afat, MD. Rieky Elise Gustina Dikmans, MD. Jan Maerten Smit, MD. Henri Adolf Hubert Winters, PhD. Johan Peter William Don Griot, PhD. et al.
Background: There is increasing interest in the use of acellular dermal matrices (ADMs) in implant-based breast reconstruction (IBBR). Suggested advantages are that ADMs facilitate one-stage IBBR and improve aesthetic outcomes. We compared immediate one-stage ADM-assisted IBBR with two-stage IBBR (current standard of care). Our previously reported secondary endpoint showed that one-stage ADM-assisted IBBR was associated with significantly more adverse outcomes. Here, we present the primary endpoint results aiming to assess whether one-stage IBBR with ADM provides higher patient-reported quality of life (QOL) compared with two-stage IBBR.